4th Immunotherapy of Cancer Conference

THE LEADING EUROPEAN CONFERENCE PROVIDING A GLOBAL PLATFORM FOR IMMUNO-ONCOLOGY

20 MARCH 2017
PRAGUE
CZECH REPUBLIC

Visit the websites:
www.cddf.org
www.itoc-conference.eu
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME LETTER</td>
<td>4</td>
</tr>
<tr>
<td>CANCER DRUG DEVELOPMENT FORUM (CDDF)</td>
<td>5</td>
</tr>
<tr>
<td>ORGANISING PARTNERS</td>
<td>5</td>
</tr>
<tr>
<td>ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)</td>
<td>6</td>
</tr>
<tr>
<td>CONFERENCE COMMITTEE</td>
<td>6</td>
</tr>
<tr>
<td>PROGRAMME AT A GLANCE</td>
<td>7</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAMME</td>
<td>8</td>
</tr>
<tr>
<td>POSTERS</td>
<td>10</td>
</tr>
<tr>
<td>FLOORPLAN</td>
<td>14</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENT</td>
<td>15</td>
</tr>
<tr>
<td>EXHIBITORS</td>
<td>16</td>
</tr>
<tr>
<td>SATELLITE SYMPOSIA</td>
<td>18</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>19</td>
</tr>
</tbody>
</table>
WELCOME LETTER

Welcome to the third edition of the Immunotherapy of Cancer Conference (ITOC-3), to help push further the opportunities that will ultimately aid in revolutionising the way cancer is treated.

This meeting is growing rapidly into a global platform for translational research in the field of immuno-oncology. Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development, the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.

For this third edition, the conference has once again surpassed our expectations in terms of attendance and participants. Our excellent scientific programme with an international faculty will focus on many topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T-cell Therapy and monoclonal antibodies with special emphasis on translational research and biomarker development.

The conference offers a broad and exciting range of opportunities and tools to gain exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC-3 in the beautiful city of Munich.

In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome. We therefore encourage you to complete the evaluation form at the end of the conference and please do not hesitate to reach out to our team on site or via email (cdff@ecco-org.eu)

Yours sincerely,

Prof. Alexander M.M. Eggermont  
Conference President

Prof. Howard Kaufman  
Conference President

Prof. Volkmar Nüssler  
Conference President

Prof. Heinz Zwierzina  
Scientific Chair
CANCER DRUG DEVELOPMENT FORUM (CDDF)

The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria.

It was established in 2001 as Biotherapy Development Association (BDA) and changed name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA’s focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organisation’s breadth of interests and activities.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can exchange expertise to find ways to expedite effective oncology drug development and delivery.

For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Meeting reports and publications based on previous workshops and events are featured in some of the leading oncology journals. You may access CDDF’s list of publications at: [www.cddf.org](http://www.cddf.org)

Be part of the discussion on the future of oncology drug development. Join us at our next conference in October in Austria!

CONFERENCE PARTNERS
CONFERENCE COMMITTEE

CONFERENCE PRESIDENTS
- Alexander M.M. Eggermont (France)
- Howard L. Kaufman (USA)
- Volkmar Nüssler (Germany)

SCIENTIFIC COMMITTEE
- Heinz Zwierzina (Austria) – Scientific Programme Committee Chair
- Paolo A. Ascierto (Italy)
- Lisa Butterfield (USA)
- Angus Dalgleish (United Kingdom)
- Stefan Endres (Germany)
- Leif Hakansson (Sweden)
- Robert Hawkins (United Kingdom)
- Samir Khleif (United States)
- Sebastian Kobold (Germany)
- José Saro (Switzerland)
- Barbara Seliger (Germany)
- Wenru Song (USA)
- Christoph Zielinski (Austria)

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)

The 3rd Immunotherapy of Cancer Conference, Munich, Germany (21-23 March 2016), has been granted 13 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country. Further information: www.acoe.be

The German Further Medical Training Certificate of Attendance (BLÄK) is available for this conference as well. For further information please contact the registration desk onsite.
# Programme at a Glance

## Monday, 21 March 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>9:00</td>
<td>Opening Plenary Symposium: New insights into the Basics of Tumour Immunology</td>
</tr>
<tr>
<td>10:10</td>
<td>Plenary Symposium Oncolytic Viruses</td>
</tr>
<tr>
<td>10:40</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary Symposium Cell Therapy</td>
</tr>
<tr>
<td>12:50</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00</td>
<td>Satellite Symposium: Broadening the Horizon of Immunotherapy in Lymphoid Malignancies</td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Symposium Biomarkers</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Viewing</td>
</tr>
<tr>
<td>19:30</td>
<td>ITOC3 Conference Dinner</td>
</tr>
</tbody>
</table>

## Tuesday, 22 March 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Plenary Symposium New Perspectives for Anti-Cancer Vaccines</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary Symposium Combination Therapy</td>
</tr>
<tr>
<td>12:50</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00</td>
<td>Satellite Symposium: Advancing Immunotherapy in Lymphoid Malignancies</td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Symposium Biomarkers</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Viewing</td>
</tr>
<tr>
<td>19:30</td>
<td>ITOC3 Conference Dinner</td>
</tr>
</tbody>
</table>

## Wednesday, 23 March 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Satellite Symposium Enhancing Cancer Immunotherapy: A Dialogue Between the Laboratory and the Clinic</td>
</tr>
<tr>
<td>9:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:10</td>
<td>Plenary Symposium Oncolytic Viruses</td>
</tr>
<tr>
<td>10:40</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary Symposium Cell Therapy</td>
</tr>
<tr>
<td>12:50</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00</td>
<td>Satellite Symposium: Enhancing Cancer Immunotherapy: A Dialogue Between the Laboratory and the Clinic</td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Symposium Biomarkers</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Viewing</td>
</tr>
<tr>
<td>19:30</td>
<td>ITOC3 Conference Dinner</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAMME

MONDAY 21 MARCH 2016

11:00-12:50
Opening Plenary Symposium: New Insights into the Basics of Tumour Immunology
Chair: H. Zwierzina (Austria)
Chair: V. Nussler (Germany)
11:00 Welcome address
Speaker: H. Zwierzina (Austria)
11:10 The network of adaptive immune resistance
Speaker: G. Adema (Netherlands)
11:35 The role of microRNAs in modulation of the immune escape of tumors
Speaker: B. Seliger (Germany)
12:00 Hypoxia and its impact on the immune system
Speaker: L. Varesio (Italy)
12:25 Novel technologies for understanding the repertoire of tumour infiltrating T cells in cancer
Speaker: S.R. Hadrup (Denmark)
12:50 Lunch
14:00 Satellite Symposium: Broadening the Horizon of Immuno-Oncology in 2016: What Happens at Bench and Bedside?
15:00 Coffee Break
15:30-17:55
Plenary Symposium: New Generation of Emerging Therapeutic Concepts
Chair: A. Dalgleish (United Kingdom)
Chair: L. Hakansson (Sweden)
15:30 Strategies to augment antitumour efficacy by inducing ADCC
Speaker: P. Sondel (USA)
15:50 Therapeutic B cell targeting in non B cell malignancies
Speaker: A. Shimabukuro-Vornhagen (Germany)
16:10 Modulation of T cell response by targeting the PI3K-Akt pathway
Speaker: S. Khleif (USA)
16:30 Modulating cancer cell metabolism as a strategy to treat haematologic malignancies
Speaker: D. Mougiakakos (Germany)
16:50 Activation of the innate immune system for therapeutic use of autophagy and apoptosis
Speaker: M.S. Soengas (Spain)
17:10 Proffered Paper: Targeting phosphatidylserine-mediated immune suppression for the treatment of cancer
Speaker: O. Wilhelm (USA)
17:25 Proffered Paper: Enhancing dendritic cell-induced T-cell responses by immunomodulating agents
Speaker: M. Rothe (Germany)
17:40 Proffered Paper: FAP-IL2v (RG7461), a novel targeted immunocytokine for cancer immunotherapy
Speaker: I. Waldhauer (Switzerland)
18:00 Welcome Reception and Poster Viewing

TUESDAY 22 MARCH 2016

08:30 - 10:30
Plenary Symposium: New Perspectives for Anti-Cancer Vaccines
Chair: W. Song (USA)
Chair: A. Dalgleish (United Kingdom)
08:30 Anti-cancer vaccination strategies
Speaker: C.J.M. Melief (Netherlands)
09:00 Targeting tumour vasculature by DNA vaccines
Speaker: A. Facciabene (USA)
09:20 Reprogramming the cancer microenvironment with vaccine-based therapy
Speaker: L. Zheng (USA)
09:40 Immune modulation by tumour antigens
Speaker: L. Butterfield (USA)
10:00 Proffered Paper: RNAdjuvant, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile
Speaker: R. Heidenreich (Germany)
10:15 Proffered Paper: Randomized, open-label phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected monosomy 3 uveal melanoma
Speaker: G. Schuler (Germany)
10:30 Coffee Break
**11:00 - 12:50**

**Plenary Symposium: Combination Therapy**
Chair: H. Kaufman (USA)
Chair: W. Song (USA)

11:00  How to interpret data from immunotherapy combination trials  
Speaker: I. Melero (Spain)

11:20  Prioritisation of potential immunotherapy combination studies  
Speaker: A. Marabelle (France)

11:40  Rationale for combining immunotherapy with chemotherapy  
Speaker: A. Dalgleish (United Kingdom)

12:00  Induction of immune response by combining TLR activation and radiotherapy  
Speaker: P. E. Huber (Germany)

12:20  Proffered Paper: Safety, immune activation and antitumor efficacy of PEGylated recombinant human IL-10 (AM0010) in patients with advanced solid tumors - a phase 1 study  
Speaker: M. Oft (USA)

12:35  Proffered Paper: Targeting melanoma with anti-MAGE A1 TCR-like single chain antibody immunoliposomes  
Speaker: M. Saeed (Netherlands)

12:50  Lunch

**14:00**

**Satellite Symposium: Advancing Immunotherapy in Lymphoid Malignancies**

15:00  Coffee Break

**15:30 - 17:30**

**Plenary Symposium: Biomarkers**
Chair: L. Butterfield (USA)
Chair: L. Hakansson (Sweden)

15:30  Biomarkers in t-cell therapy trials  
Speaker: J. Galon (France)

15:50  Biomarker development for immunotherapy using peripheral blood  
Speaker: R. Sullivan (USA)

16:10  Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomised phase II study (POPLAR)  
Speaker: L. Paz-Ares (Spain)

16:30  PD-L1 expression as a potential predictive biomarker  
Speaker: P. A. Ascierto (Italy)

16:50  Biomarker design for combination trials  
Speaker: S. Khleif (USA)

17:30  Poster Viewing

---

**23 March 2016**

**08:00**

**Satellite Symposium: Enhancing Cancer Immunotherapy: A Dialogue Between the Laboratory and the Clinic**

**09:00 - 10:10**

**Plenary Symposium: Oncolytic Viruses**
Chair: R. Hawkins (United Kingdom)
Chair: S. Khleif (USA)

09:00  Oncolytic viruses: A new class of immunotherapy drugs  
Speaker: H. Kaufman (USA)

09:30  Boosting immueresponse by a modified vesicular stomatitis virus (VSV)  
Speaker: D. Von Laer (Austria)

09:50  Combination of viroimmunotherapy with checkpoint inhibitors  
Speaker: A. Melcher (United Kingdom)

10:10  Coffee Break

**10:40 - 12:10**

**Plenary Symposium: Cell Therapy**
Chair: S. Kobold (Germany)
Chair: B. Seliger (Germany)

10:40  CAR T cell therapy  
Speaker: R. Hawkins (United Kingdom)

11:10  Enabling T cell recruitment at the tumor site as a strategy to improve efficacy of adoptive T cell therapy  
Speaker: S. Kobold (Germany)

11:30  Regulating Tregs to enhance adoptive T cell therapy of cancer  
Speaker: Z. Li (USA)

11:50  T cell potentiation in tumor draining lymph nodes through local administration of CpG or anti-CTLA4  
Speaker: T. de Gruijl (Netherlands)

12:10  Closing Remarks
POSTERS

Posters are on display in the pavilion. Poster abstracts and author details are listed in the ITOC-3 Abstract Supplement.

**Poster Session: Immune Regulation**

- **Expression of immune checkpoint molecules and activation markers in T cells from chronic lymphocytic leukemia (CLL) patients**

- **Tumour-associated lymphocytes and macrophages can facilitate the epigenetic shifts resulting in cancer cell stemness**
  V. Halytskiy (Ukraine)

- **A subset of human LAG-3+ Tregs shows characteristics of follicular Tregs**
  C. Camisaschi, L. De Cecco, B. Vergani, V. Beretta, F. Rini, A. Cabras, G. Cutrona, M. Di Nicola, M. Milione, F. Arienti, A. Villa, L. Rivoltini, C. Castelli (Italy)

- **Hypoxic/acidic tumour microenvironment could be linked to inflammatorypressive cells and may induce an aggressive phenotype in human hepatocellular carcinoma**
  A. Tuccitto, O. Kuchuk, D. Citterio, V. Beretta, F. Rini, A. Cova, V. Huber, M. Milione, A. Villa, B. Vergani, P. Squarcina, D. Giardiello, L. Mariani, V. Mazzaferro, L. Rivoltini, C. Castelli (Italy)

- **Indirect presentation of Y-chromosome antigen DBY requires protein structures outside of the T-cell epitope**
  S. Kretschmann, H. Bruns, A. Mackensen, A. Kremer (Germany)

- **Evaluation of new TLR9 agonists for immunotherapy: Enantiomeric oligonucleotides (EnanDIM®)**
  K. Kapp, M. Schmidt, B. Wittig, M. Schroff, C. Kleuss (Germany)

- **Tumor-associated macrophages as a prognostic marker for prostate cancer progression**
  M. Athelogou, H. Hessel, N. Harder, A. Buchner, N. Brieu, M. Yigitsoy, R. Schoenmeyer, A. Schaepe, G. Schmidt, C. Stief, T. Kirchner, G. Binnig (Germany)

- **Surface staining of PD-1 discriminates dead from viable MDSCs**
  P. Metzger, S. Kirchleitner, I. Ritter, S. Endres, P. Duewell, M. Schnurr (Germany)

- **New mediators of immunogenic cell death induced tumor control**
  B. Seliger, D. Quandt (Germany)
**Poster Session: Preclinical Models**

**Abstract/Poster Numbers**

**B16-F10 melanoma immunotherapy based on anchoring of ligands stimulating phagocytosis to tumor cells surface**

J. Zenka, V. Caisova, T. Janotova, M. Auerova, V. Maierova, E. Waldmannova, M. Kvaroova, A. Jackova, N. Vacova, J. Kopecky (Czech Republic)

**Innate immunity based cancer immunotherapy with possible application in human medicine**


**Syngeneic tumor mouse models vary in their response to different immune checkpoint inhibitor treatment**

P. Jantscheff, C. Schaefer-Obodozie, S. Moor, H. Weber (Germany)

**Novel kinetic live cell imaging assays for immune cell killing of tumour cells**

N. Rodionova, N. Bevan, C. Szybut, T. O’Callaghan, T. Dale, D. Trezise (Germany)

**Profiling compounds in human primary cell systems for drug discovery and development in cancer immunotherapy**

A. Saharia, A. O’Mahoney, J. Ptacek, J. Melrose, K. Matta, E. Berg (United Kingdom)

**Tumour forming efficiencies of TUBO cell line expressing Her2 in two different mice strains with Matrigel matrix to develop animal models for novel immunotherapies**

M. Anil, S. Gulce Iz, P. Saglam Metiner, E. Atalay Sahar, H. Can, O. Zekioglu, M. Doskaya, L. Yeniay (Turkey)

**Bifunctional peptide-MHC class I antibody fusions selectively activate CD8+ T cells to eliminate tumor cells in vivo**

C. Fischer, F. Herting, S. Imhof-Jung, E. Hoffmann, P. Umana, C. Klein, H. Knoetgen (Germany)

**Improving selective lysis of leukemia cells via dual-targeting antibody-derivatives**

C.C. Roskopf, T.A. Braciak, N.C. Fenn, S. Kobold, G.H. Fey, K.P. Hopfner, F.S. Oduncu (Germany)

**Development of preclinical in vitro and in vivo models to test antitumor efficacy of human anti-checkpoint antibodies**

M.J. Tosiek, C. Barriere, E. Serres, M. Rathaux, S. D’Agostino, P. Ferrari, B. Dumas, S.S. Sidhu (France)

**Understanding the effect mechanism through the good biomarker: Anti-PD-L1 immunotherapy**

A. Contreras, M. Merino, P. Berraondo, M. Garrido (Spain)

**Modulating impact of leukocytes on drug response in primary colorectal cancer spheroids**

B. Mayer, K. Weiler, M. Joka, J. Werner, C. Ilmberger (Germany)

**Infiltrating lymphocyte subpopulations in cancer microtissues: potential biomarkers for the identification of novel immunomodulatory agents**

S. Koeck, A. Amann, M. Zwierzina, G. Gamerith, E. Lorenz, J. Kelm, J. Kern (Austria)

**The influence of stromal cells on immune cell infiltration in 3D cancer microtissues**

A. Amann, S. Koeck, J. Kern, M. Zwierzina, G. Gamerith, E. Lorenz, J. Kelm, H. Zwierzina (Austria)

**Poster Session: Co-Stimulatory Agonists and Co-Inhibitory Antagonists**

**A novel synthetic Toll-like-receptor 7 agonist activates NK cells for tumor therapy**

G.M. Wiedemann, S. Jacobi, M. Chaloupka, S. Hamm, S. Strobl, B. Baumgartner, S. Endres, S. Kobold (Germany)

**Hexavalent agonists targeting receptors of the tumor necrosis factor superfamily: TRAIL, CD40L, CD27L and beyond**

D.M. Richards, C. Gieffers, M. Kluge, C. Merz, T. Schnyder, J. Sykora, M. Thiemann, H. Fricke, O. Hill (Germany)

**Target-specific costimulatory T-cell engagement by the HER2/CD137 bispecific PRS-343**

M.J. Hinner, R.S. Bel Alba, C. Schlosser, A. Wiedenmann, A. Allersdorfer, G. Matschiner, S. Berger, U. Moebius, C. Rothe, S. Olwill (Germany)

**Poster Session: Immunogenomics**

**Direct identification of neo-epitopes using in-depth immunopeptidomics of melanoma tissues for the development of anti-tumor immunotherapies**

**Poster Session: Therapeutic Modulation of Immune Checkpoints**

**Therapeutic effect of immune reaction due to cryoablation**

S. Osada (Japan)

**Improved cell-based assays to assess therapeutic molecules against immune checkpoint receptors such as PD-1, PD-L1 and PD-L2**

A. Saharia, J. Lin-Jones, H. Daino-Laizure, M. Nguyen, J. Lamerdin (United Kingdom)

**Specific neutralization on cancer cells with dual targeting αvβ3 bodies for efficacious yet safe anti-CD47 therapies**


**Synergy achieved when co-engaging CD47 and CD19 as targets in B cell malignancies**


**APG101 is a potent blocker of pro-apoptotic CD95/CD95L signaling and protects immune cells from activation-induced cell death**

C. Merz, J. Sykora, T. Beyer, D. Richards, H. Fricke, C. Gieffers (Germany)

**Immune checkpoint blockade in melanoma by new targeted Dox immunoliposomes**

M. Merino Díaz, A. M. Contreras Sandoval, K. Berraondo, M.J. Garrido Cid (Spain)

**Changes in plasma HMGB1 concentration during conventional treatment of lung adenocarcinoma patients are associated with overall survival**

D. Aguilar-Cazares, M. Meneses-Flores, C. Camacho-Mendoza, H. Prado-Garcia, M. Galicia-Velasco, J.S. Lopez-Gonzalez (Mexico)

**Poster Session: Combination Therapy**

**Strategy for synchronous and multiple liver metastasis**

S. Osada (Japan)

**Tumor cell death induced by modulated electrophoretic tumor induction with Marsdenia tenacissima in murine colorectal allograft tumor model**

N. Megyveshazi, C. Kovago, T. Vancsiő, E. Kiss, T. Krenacs (Hungary)

**Synergy of combined immune checkpoint modulation and CD30/CD16A-TandAb-induced NK-cell-mediated target cell lysis enhances tumor eradication in vivo**

X. Zhao, N. Rajasekaran, U. Reusch, J.P. Marschner, M. Treder, H. Kohrt (Germany)

**Custom made fibroblast-specific and antibiotic-free interleukin-12 plasmid for electrotroanapherasing mediated cancer immunotherapy**

U. Kamensek, S. Kos, N. Tesic, G. Serša, M. Cemazar (Slovenia)

**Use of monoclonal antibodies against a membrane tetraspanin for metastasis control of colorectal cancer**

R. Grenfell, N. Almeida, W. Jeremias, D. Taboada, V. Silva-Moraes, R. Davis (Brazil)

**A novel LSD1/HDAC inhibitor 4SC-202 inhibits immunosuppressive MDSC and enhances immunogenicity of tumor cells by up-regulation of TAA expression**

S. Hamm, K. Kronthaler, U. Parntitzke, T. Prenzel, H. Kohlhof, D. Vitt, R. Baumgartner (Germany)

**Feasibility study of NK cell therapy against cancer**

T. Shinohara, J. Masuyama, K. Tada, Y. Sato, S. Uyama, Takaue, Y(1), Y. Heike (Japan)

**Poster Session: Anti-Cancer Vaccines**

**Re reflating Coley: Active metronomic fever therapy using PRRL and approved drugs**

U. Hobohm (Germany)

**Activation of the cytosolic RNA receptor RIG-I in tumor and immune cells triggers efficient anti-tumor immunity and synergizes with checkpoint blockade**


**Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I/II trial**


**Comparison of the effect for a native and recombinant vitamin D binding protein derived macrophage activation factor, with a synthetic polypeptide on human breast carcinoma and murine macrophage cultures**

P. Smith, E. Ward (United Kingdom)
Immunemodulation of AML-blasts with clinically approved response modifiers improves antileukemic T-cell reactivity ex vivo and leads to blast-reduction in vivo (rat-model)

70-kDa heat shock protein coated magnetic nanoparticles as a nanovaccine for immunotherapy of experimental glioblastoma
M. Shevtsov, B. Nikolaev, L. Yakovleva, Y. Marchenko, M. Parr, A. Dobrodumov, E. Pitkin, G. Multhoff (Germany)

Identification of potential immune targets in controlling Endometrioid Endometrial Carcinoma metastatic progression.
J.N. Billaud, E. Dubus, S. Tugendreich, D. Toburen

Active immunotherapy based on HER1 and HER2 oncogenes as an alternative strategy to treat cancer patients

Transduction with C-C-chemokine receptor type 4 (CCR4) enhances tumor-specific migration of adoptively transferred T cells in a model of pancreatic cancer
M. Rapp, S. Grassmann, F. Rataj, S. Endres, D. Anz, S. Kobold (Germany)

Double strike approach for tumor attack: Improving T cell functionality and targeting tumor stroma
L.F. Olguin-Contreras, A. Mendler, E. Noessner (Germany)

The generation of CD8+ T cells expressing two additional receptors (TETARs) for the use in a multiple-hit immunotherapy against melanoma
U. Uslu, G. Schuler, J. Dörrie, N. Schaft (Germany)

A study to assess the feasibility of converting intra marrow CD8 lymphocytes from acute myeloid leukemia patients into central memory state by reactivation in SIP (Simulated Infective Protocol)
S.L. Poh, Y.W. Teo, S. Li, Y.T. Goh, Y.C. Linn, L.P. Ho (Singapore)

Pharmacodynamic biomarkers for first in class early phase immuno-oncology trials; opportunities and challenges

Do we have a correct selection of patients? Our experience with ipilimumab

Liposomes encapsulating zoledronic acid for cancer immunotherapy and their effect on the in vivo biodistribution of Vg9/Vd2 T cells in different tumour models
N. Hodgins, J. Wang, A. Parente Pereira, W. Al-jamal, J. Maher, K. Al-jamal (United Kingdom)

BRCA 1 Status and its association with family history
A. Fatima (Pakistan)

Discovery of novel biomarkers based on spatial immune cell patterns: A disease-overarching image mining approach bridging biopsy evaluation in oncoimmunology and transplantation medicine
R. Schömeyer, N.S. Schaadt, A. Schäpe, V. Matvienko, W. Gwinner, J.H. Bräsen, S. Althammer, M. Vigitsyo, N. Brieu, G. Schmidt, G. Binnig, F. Feuerhake (Germany)

Changing the face of lung cancer

Biomarker development for cancer immuno-oncology/immunotherapy: Simultaneous digital counting of nucleic acids and proteins at 800-plex
J. White, J. Beechem, S. Warren, G. Demirkan, C. Bailey, L. Dennis, I. Pekker, A. Cesano (United Kingdom)

Near complete remission in a stage IV triple negative breast cancer (TNBC) with low-dose checkpoint inhibitors in combination with high dose interleukin-2 (IL-2) and fever range whole body hyperthermia
R. Kleef, R. Moss, M. Szasz, A. Bohdjalian, T. Bakacs

Immune checkpoint and immunostimulatory reporter bioassays to advance the development of therapeutic antibodies in immunotherapy research programs
ACKNOWLEDGEMENT

The conference is very grateful to the following companies for their generous support to ITOC-3.

PLATINUM SPONSORS

Bristol-Myers Squibb

Celgene

Roche
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease, cardiovascular and metabolic disease and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our focus for the future of cancer care is on Immuno-Oncology. We have a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, many of which were discovered and developed by our scientists. For more information about Bristol-Myers Squibb, visit www.b-ms.de.

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for cancer and other severe, immune, inflammatory conditions. Celgene employs more than 5,300 employees worldwide.

CellGenix is a premium supplier of high-quality ancillary products, reagents and tools for cell therapy and regenerative medicine. Our cytokines and serum-free media are manufactured in accordance with the relevant cGMP, Ph. Eur., USP, and ICH guidelines. CellGenix offers a comprehensive product portfolio for the seamless transition from research to commercialization.

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.

The IncuCyte® Real-Time Quantitative Live-Cell Analysis System, designed by Essen BioScience, Inc. is the first system to enable quantification of cell behavior over time (from hours to weeks) by automatically gathering and analyzing images around the clock within a stand incubator. The IncuCyte® System provides insight into active biological processes in real-time and allows researchers to gather more information from assays they conduct in a faster and automated way that single-point or endpoint assays can’t achieve. In addition to the IncuCyte® instrumentation, Essen BioScience also provides reagents and analysis software which enable researchers to perform real-time, quantitative live cell analysis and evaluate a wide variety of cellular processes over time within a standard laboratory incubator.

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Macopharma has developed a wide range of products in the fields of cell & tissue therapy, regenerative medicine and transplantation. The biotherapy range of products provides solutions for every step of the cellular therapy process from collection, processing, expansion and cryopreservation of stem cells, up to the treatment and transplantation of cells or organs to patients.

MiltiBiotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our more than 25 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. MiltiBiotec has more than 1,500 employees in 25 countries.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System, which has been employed in basic and translational research and cited in 500 peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System and uses the nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay.

ProQinase is a leading service provider for anti-cancer drug development. Apart from biochemical and cell-based assay services, the company offers a broad range of mouse tumor models including subcutaneous, orthotopic and metastasis models. Our immuno-oncology platform comprises several syngeneic models and supporting immunoassays for their analysis. Our strengths are custom-tailored solutions for the testing of your drug or immunotherapeutic.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. For more information, please visit roche.com.
# SATELLITE SYMPOSIA

## 21 March 2016
### SATELLITE SYMPOSIUM 14:00-15:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 | **Checkpoint Inhibition: A glance at early data of I-O therapy and at further tumor entities**  
Speaker: I. Melero (Spain)  
**Checkpoint Inhibition: A glance at new approaches in haematology**  
Speaker: W. Herr (Germany)  
**Clinical breakthrough in immunooncology: Taking a glance at the bedside**  
Speaker: A. Krackhardt (Germany) |

## 22 March 2016
### SATELLITE SYMPOSIUM 14:00-15:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 | **Targeting the immune checkpoint network in lymphoid malignancy**  
Speaker: A.G. Ramsay (United Kingdom)  
**Present experience and enhanced engineering of CAR T cell therapy for B-cell malignancies**  
Speaker: M. Jensen (USA) |

## 23 March 2016
### SATELLITE SYMPOSIUM 08:00-09:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:00 | **Welcome**  
Speaker: C. Ottensmeier (United Kingdom)  
**What has checkpoint inhibition taught us about the tumour microenvironment?**  
Speakers: A. Marabelle (France) and S. Peters (Switzerland)  
**Forging the future for cancer immunotherapy**  
Speakers: A. Marabelle (France) and S. Peters (Switzerland)  
**Panel Discussion** |
GENERAL INFORMATION

SECRETARIAT

Cancer Drug Development Forum
c/o ECCO – the European CanCer Organisation
Avenue E. Mounier, 83
B-1200 Brussels, Belgium
Tel.: +32 (0) 2 775 02 01
email: cddf@ecco-org.eu

CONFERENCE VENUE

Hörsaal A (Auditorium A)
Klinikum Rechts der Isar
Entrance Einstein Strasse
TU Munich Ismaniger Str. 22
81675 Munich, Germany

HOW TO REACH THE VENUE

The Klinikum Rechts der Isar is very accessible by public transport. From the Hilton Munich City (ITOC-3 official hotel), take tram 16 at tram stop Am Gasteig in the direction of Max-Weber-Platz.

The Klinikum is also reachable by Ubahn U4 and U5 – station Max-Weber-Platz.

Please note that the best entrance of the conference is not the Klinikum main entrance on Ismaniger Strasse but via the entrance on the Einstein Strasse, as indicated below.
REGISTRATION

ITOC-3 is open to all registered participants. Your official delegate name badge is required for admission to the conference centre and all conference events. For security reasons, participants are requested to wear their badge at all times.

Registration Opening Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, 21 MARCH</td>
<td>09:00 - 17:30</td>
</tr>
<tr>
<td>TUESDAY, 22 MARCH</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>WEDNESDAY, 23 MARCH</td>
<td>07:30 - 14:00</td>
</tr>
</tbody>
</table>

Registration Fees

FULL CONFERENCE FEE

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADEMIA</td>
<td>650 EUR</td>
</tr>
<tr>
<td>INDUSTRY</td>
<td>950 EUR</td>
</tr>
<tr>
<td>STUDENT*</td>
<td>175 EUR</td>
</tr>
</tbody>
</table>

*Appropriate and valid student identification should be provided.

ONE DAY CONFERENCE FEE

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADEMIA</td>
<td>175 EUR</td>
</tr>
<tr>
<td>INDUSTRY</td>
<td>275 EUR</td>
</tr>
</tbody>
</table>

BADGES

For security reasons, delegates are requested to wear their badge at all times during the conference. Delegates having lost their badge can obtain a new badge at the registration desk. A replacement fee may be charged.

CATERING

Coffee breaks, lunches and a welcome reception have been scheduled. Exact times are listed in the programme overview.

CERTIFICATE OF ATTENDANCE

A Certificate of Attendance recording CME credits may be printed via the conference website at www.ecco-org.eu/itoc3 as of Tuesday 22 March (12:00 PM).

You will be requested to enter your badge code number to log in and to complete a short questionnaire before obtaining your certificate. Please keep your badge to print your certificate.
CONFERENCE DINNER

SPATENHAUS: A UNIQUE VENUE FOR A WARM AND FRIENDLY NETWORKING EVENING

Date: 22 March starting at 19:30
This dinner and networking evening is organised for Conference delegates as an opportunity for even more memorable interactions among peers.

A true institution in Munich, the Spatenhaus is located in the middle of the city at the Max-Joseph-Platz, with breathtaking views of the Bavarian National Theatre, Residence and the Palais an der Oper. The Spatenhaus is known for its exquisite and authentic German cuisine perfectly catering for all tastes.

Tickets may be purchased on site at the registration desk but availability may be limited.

EXHIBITION

The exhibition is held in the foyer of the conference centre. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

INSURANCE

The organisers of ITOC-3 do not accept liability for individual medical, travel or personal insurance. Participants are strongly recommended to obtain their own personal insurance policies. The organisers of ITOC-3 accept no responsibility for loss due to theft or negligence.

LANGUAGE & TRANSLATION

The official language of the conference is English. No simultaneous translation is provided.

LOST & FOUND

All enquiries should be directed to the registration desk in the entrance hall. The organisers accept no responsibility for loss due to theft or negligence.

POLICIES

ITOC-3 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC-3 Conference asks delegates and faculty to refrain from taking children and accompanying adults to any scientific sessions or practical demonstrations. In the event that children are required to enter the conference centre they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC Conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.
We are building on our strong heritage in hematology and immune modulation to help shape the future of immuno-oncology by developing innovative therapies that target multiple immune cell types.
Enhancing cancer immunotherapy: A dialogue between the laboratory and the clinic

Wednesday 23 March 2016
08.00–09.00
Main Auditorium, Munich Tumour Centre, Germany

08.00–08.15  Welcome and introduction
Christian Ottensmeier (Southampton, UK)

08.15–08.30  What has checkpoint inhibition taught us about the tumour microenvironment?
Aurélien Marabelle (Villejuif, France) and Solange Peters (Lausanne, Switzerland)

08.30–08.50  Forging the future for cancer immunotherapy
Aurélien Marabelle (Villejuif, France) and Solange Peters (Lausanne, Switzerland)

08.50–09.00  Panel discussion
All faculty
Certainly we cannot treat all tumor types. But we are broadening the horizon of cancer treatment.

Immuno-Oncology by Bristol-Myers Squibb

Monday 21st of March 2016, 14:00 – 15:00
Klinikum rechts der Isar, TU Munich, Ismaniger Straße 22, 81675 Munich – Germany

Broadening the horizon of Immuno-Oncology in 2016: What happens at bench and bedside?
Chair: Prof. Angela Krackhardt (Munich, Germany)

14:00 – 14:05 Welcome
Prof. Angela Krackhardt (Munich, Germany)

14:10 – 14:25 Checkpoint Inhibition: A glance at early data of I-O therapy and further tumor entities
Prof. Ignacio Melero (Pamplona, Spain)

14:25 – 14:40 Checkpoint Inhibition: A glance at new approaches in Haematology
Prof. Wolfgang Herr (Ratisbon, Germany)

14:40 – 14:55 Clinical Breakthrough in Immuno-Oncology: Taking a glance at the bedside
Prof. Angela Krackhardt (Munich, Germany)

14:55 – 15:00 Discussion and closing remarks
Prof. Krackhardt, Prof. Herr, Prof. Melero